OncoSec Medical is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. Co.'s main technology platform ImmunoPulse® is a drug-device therapeutic modality platform comprised of proprietary intratumoral electroporation (EP) delivery devices (the OncoSec Medical System (OMS) EP Device). The OMS EP Device is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunological response against cancer.Co.'s main product candidate is a DNA-encoded interleukin-12 called tavokinogene telseplasmid. The ONCS stock yearly return is shown above.
The yearly return on the ONCS stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ONCS annual return calculation with any dividends reinvested as applicable (on ex-dates).
|